- Home
- BODI vs ATNM Comparison
BODI vs ATNM Comparison
Compare BODI & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BODI
- ATNM
- Stock Information
- Founded
- BODI 1998
- ATNM 2000
- Country
- BODI United States
- ATNM United States
- Employees
- BODI N/A
- ATNM N/A
- Industry
- BODI Industrial Machinery/Components
- ATNM Biotechnology: Pharmaceutical Preparations
- Sector
- BODI Industrials
- ATNM Health Care
- Exchange
- BODI Nasdaq
- ATNM Nasdaq
- Market Cap
- BODI 49.0M
- ATNM 46.5M
- IPO Year
- BODI N/A
- ATNM N/A
- Fundamental
- Price
- BODI $6.05
- ATNM $1.38
- Analyst Decision
- BODI Strong Buy
- ATNM Strong Buy
- Analyst Count
- BODI 3
- ATNM 4
- Target Price
- BODI $10.67
- ATNM $8.75
- AVG Volume (30 Days)
- BODI 13.5K
- ATNM 1.4M
- Earning Date
- BODI 05-05-2025
- ATNM 04-25-2025
- Dividend Yield
- BODI N/A
- ATNM N/A
- EPS Growth
- BODI N/A
- ATNM N/A
- EPS
- BODI N/A
- ATNM N/A
- Revenue
- BODI $418,796,000.00
- ATNM N/A
- Revenue This Year
- BODI N/A
- ATNM N/A
- Revenue Next Year
- BODI $1.13
- ATNM N/A
- P/E Ratio
- BODI N/A
- ATNM N/A
- Revenue Growth
- BODI N/A
- ATNM N/A
- 52 Week Low
- BODI $5.14
- ATNM $1.03
- 52 Week High
- BODI $10.80
- ATNM $10.24
- Technical
- Relative Strength Index (RSI)
- BODI 37.10
- ATNM 48.59
- Support Level
- BODI $6.61
- ATNM $1.41
- Resistance Level
- BODI $7.55
- ATNM $2.41
- Average True Range (ATR)
- BODI 0.69
- ATNM 0.25
- MACD
- BODI -0.15
- ATNM -0.01
- Stochastic Oscillator
- BODI 0.00
- ATNM 17.60
About BODI The Beachbody Company Inc. Class A Common Stock
The Beachbody Co Inc is a health and wellness platform providing fitness, nutrition and stress-reducing programs to its customers. The product offerings of the company include Digital Subscriptions, Nutritional Products, and Connected Fitness Products. It earns the majority of its revenue from the United States. The company operates and manages its business in two operating segments, Beachbody and Other.
About ATNM Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.